Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MicroRNA Momentum Builds, But Will Big Pharma Embrace It?

Executive Summary

While interest in microRNA may not be moving at the speed that some investors (and, certainly, some smaller companies) may like, Big Pharma has taken notice of the little oligos and is watching the sector.


Related Content

Santaris, BMS Partner To Develop Therapeutics Targeting miRNA
AstraZeneca Taps Regulus For microRNA Drug Development
Finding Gold In An Unfavored Space: Servier And MicroRNA Start Up Miragen In CV Deal
Pfizer Expands Santaris Deal to Boost Presence in RNA-Targeted Drug Development
Roche Exits RNAi, Raising Questions For Stalwarts
Sanofi Moves into MicroRNA, Signs Preclinical Platform Deal with Regulus
GSK Doubles Up With Regulus, Signing New Collaboration For HCV Therapeutics
GSK Partners With Santaris On RNA Antagonists For Viral Disease
Starlight Success: Isis, Alnylam Form Regulus To Develop MicroRNA Antagonists


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts